



## Streptococcus: Biology, Pathogenesis, Epidemiology and Evolution

Guest Editors:

**Prof. Dr. Tatiana Castro Abreu Pinto**

Instituto de Microbiologia Paulo de Goes, Universidade Federal Do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil

**Prof. Dr. Felipe Piedade Gonçalves Neves**

Instituto Biomédico, Universidade Federal Fluminense, Niterói 24020-150, RJ, Brazil

Deadline for manuscript submissions:

**30 July 2024**

### Message from the Guest Editors

Dear Colleagues,

Streptococci are Gram-positive, catalase-negative cocci. Certain streptococcal species show a high degree of host and disease specificity, while others can cause a wide array of different pathologies in distinct hosts. Some species are recognized as classical pathogens for humans and/or other animals, while others are typically opportunistic. Some of these opportunists, however, are becoming increasingly important, due to their ability to acquire new mechanisms of antimicrobial resistance. Streptococcal species are also emerging in the One Health context, and some of them have been associated with zoonotic infections. The increasing relevance of streptococci in new and reemerging diseases as well as in antimicrobial resistance has boosted many initiatives for vaccine development. Elucidating aspects of the biology, pathogenesis, and evolution of streptococci, especially using novel genomic and proteomic approaches, will help us to better understand this complex group of microorganisms and lead to improved measures to prevent and control streptococcal infections.

Prof. Dr. Tatiana Castro Abreu Pinto

Prof. Dr. Felipe Piedade Gonçalves Neves





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)